Chapter title |
RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?
|
---|---|
Chapter number | 20 |
Book title |
RUNX Proteins in Development and Cancer
|
Published in |
Advances in experimental medicine and biology, March 2017
|
DOI | 10.1007/978-981-10-3233-2_20 |
Pubmed ID | |
Book ISBNs |
978-9-81-103231-8, 978-9-81-103233-2
|
Authors |
Jung-Won Lee, Andre van Wijnen, Suk-Chul Bae |
Editors |
Yoram Groner, Yoshiaki Ito, Paul Liu, James C. Neil, Nancy A. Speck, Andre van Wijnen |
Abstract |
RUNX family members play pivotal roles in both normal development and neoplasia. In particular, RUNX1 and RUNX2 are essential for determination of the hematopoietic and osteogenic lineages, respectively. RUNX3 is involved in lineage determination of various types of epithelial cells. Analysis of mouse models and human cancer specimens revealed that RUNX3 acts as a tumor suppressor via multiple mechanisms. p53-related pathways play central roles in tumor suppression through the DNA damage response and oncogene surveillance, and RUNX3 is involved in both processes. In response to DNA damage, RUNX3 facilitates p53 phosphorylation by the ATM/ATR pathway and p53 acetylation by p300. When oncogenes are activated, RUNX3 induces ARF, thereby stabilizing p53. Here, we summarize the molecular mechanisms underlying the p53-mediated tumor-suppressor activity of RUNX3. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 9 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 2 | 22% |
Professor > Associate Professor | 2 | 22% |
Researcher | 2 | 22% |
Student > Master | 1 | 11% |
Unknown | 2 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 3 | 33% |
Business, Management and Accounting | 1 | 11% |
Computer Science | 1 | 11% |
Neuroscience | 1 | 11% |
Unknown | 3 | 33% |